Cargando...
COVID-19 and Disease-Modifying Anti-rheumatic Drugs
PURPOSE OF REVIEW: Patients on disease-modifying anti-rheumatic drugs (DMARDs) remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several DMARDs have been proposed as COVID-19 therapies. RECENT FINDINGS: In patients with autoimmune diseases, baseline glucocorticoid use is...
Gardado en:
| Publicado en: | Curr Rheumatol Rep |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer US
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8065312/ https://ncbi.nlm.nih.gov/pubmed/33893890 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11926-021-00998-9 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|